OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: Ovarian cancer

One page to bring and write on: your details, the questions for Ovarian cancer plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Ovarian cancer

Prepared with OnCo (onco.cc/prep/ovarian/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

46 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example BRCA1/2, HRD, FRα IHC, CDH6, CA-125), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
  5. 5.For my situation (newly diagnosed), which of the standard options do you recommend and why?
  6. 6.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Olaparib or related drugs, and what side effects should I expect?
Platinum-sensitive relapse
  1. 7.For my situation (platinum-sensitive relapse), which of the standard options do you recommend and why?
Platinum-resistant
  1. 8.For my situation (platinum-resistant), which of the standard options do you recommend and why?
  2. 9.Am I a candidate for Mirvetuximab soravtansine, Relacorilant, Pembrolizumab, and what side effects should I expect?
Prevention and risk
  1. 10.For my situation (prevention and risk), which of the standard options do you recommend and why?
  2. 11.How do the results of UKCTOCS apply to someone like me?
Newly diagnosed stage I-II
  1. 12.For my situation (newly diagnosed stage i-ii), which of the standard options do you recommend and why?
  2. 13.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, and what side effects should I expect?
Newly diagnosed stage III-IV: surgery and chemotherapy
  1. 14.For my situation (newly diagnosed stage iii-iv: surgery and chemotherapy), which of the standard options do you recommend and why?
  2. 15.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Bevacizumab, and what side effects should I expect?
  3. 16.How do the results of OVHIPEC-1 and GOG-0218 & ICON7 (bevacizumab) apply to someone like me?
First-line maintenance, BRCA-mutated
  1. 17.For my situation (first-line maintenance, brca-mutated), which of the standard options do you recommend and why?
  2. 18.Am I a candidate for Olaparib, Niraparib, and what side effects should I expect?
  3. 19.How do the results of SOLO-1 and PAOLA-1 / ENGOT-ov25 apply to someone like me?
First-line maintenance, HRD-positive BRCA-wild-type
  1. 20.For my situation (first-line maintenance, hrd-positive brca-wild-type), which of the standard options do you recommend and why?
  2. 21.Am I a candidate for Olaparib, Bevacizumab, Niraparib, and what side effects should I expect?
  3. 22.How do the results of PAOLA-1 / ENGOT-ov25 apply to someone like me?
First-line maintenance, HRD-negative
  1. 23.For my situation (first-line maintenance, hrd-negative), which of the standard options do you recommend and why?
  2. 24.Am I a candidate for Bevacizumab, Niraparib, and what side effects should I expect?
  3. 25.How do the results of PRIMA / ENGOT-OV26 apply to someone like me?
Platinum-sensitive relapse (interval >6 months)
  1. 26.For my situation (platinum-sensitive relapse (interval >6 months)), which of the standard options do you recommend and why?
  2. 27.Am I a candidate for Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab or related drugs, and what side effects should I expect?
  3. 28.How do the results of DESKTOP III / ENGOT-ov20 apply to someone like me?
Platinum-resistant relapse, FRα-high
  1. 29.For my situation (platinum-resistant relapse, frα-high), which of the standard options do you recommend and why?
  2. 30.Am I a candidate for Mirvetuximab soravtansine, and what side effects should I expect?
  3. 31.How do the results of MIRASOL / GOG-3045 apply to someone like me?
Platinum-resistant relapse, PD-L1 CPS ≥1
  1. 32.For my situation (platinum-resistant relapse, pd-l1 cps ≥1), which of the standard options do you recommend and why?
  2. 33.Am I a candidate for Pembrolizumab, Paclitaxel / nab-paclitaxel, Bevacizumab, and what side effects should I expect?
  3. 34.How do the results of KEYNOTE-B96 / ENGOT-ov65 apply to someone like me?
Platinum-resistant relapse, other
  1. 35.For my situation (platinum-resistant relapse, other), which of the standard options do you recommend and why?
  2. 36.Am I a candidate for Relacorilant, Pegylated liposomal doxorubicin, Bevacizumab or related drugs, and what side effects should I expect?
  3. 37.How do the results of ROSELLA / GOG-3073 apply to someone like me?
Low-grade serous carcinoma
  1. 38.For my situation (low-grade serous carcinoma), which of the standard options do you recommend and why?
  2. 39.Am I a candidate for Letrozole (and other aromatase inhibitors), Avutometinib + defactinib, and what side effects should I expect?
  3. 40.How do the results of RAMP 201 apply to someone like me?
Rare histologies
  1. 41.For my situation (rare histologies), which of the standard options do you recommend and why?
Any stage
  1. 42.Are there clinical trials I could join, for example of Raludotatug deruxtecan, Puxitatug samrotecan, PARP PET, Galleri?
  2. 43.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 44.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 45.I read that “No effective screening”. How does that affect my plan?
  5. 46.I read that “PARP resistance via BRCA reversion”. How does that affect my plan?

The words I may hear

  • Low-grade serous ovarian cancer (LGSOC): Low-grade serous ovarian cancer is a slow-growing, RAS-driven type of ovarian cancer that resists chemotherapy but responds to hormone blockers and MEK-pathway drugs.
  • High-grade serous ovarian carcinoma (HGSOC): High-grade serous ovarian carcinoma is the most common type of ovarian cancer and the one most often found late; it actually starts in the fallopian tube and almost always has a broken TP53 gene, and it is the type PARP inhibitors were built for.
  • CA-125: A blood protein that rises in most ovarian cancers; useful for tracking treatment, useless for screening on its own.
  • Synthetic lethality: Two genes where losing either alone is fine but losing both kills the cell.
  • Debulking (cytoreductive surgery): Surgery that removes as much tumour as possible when it cannot all be removed cleanly; leaving nothing visible behind is what matters.
  • Intraperitoneal (IP) chemotherapy: Delivering chemotherapy directly into the abdominal cavity through a catheter, so the tumour deposits on the lining get a far higher dose than the rest of the body would tolerate.
  • Salpingo-oophorectomy: Removing the ovaries and fallopian tubes.
  • Platinum-sensitive / platinum-resistant: Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed).
  • HIPEC (hyperthermic intraperitoneal chemotherapy): After surgeons remove all visible tumour from the abdominal lining, the abdomen is bathed for 60-90 minutes in heated chemotherapy to kill the microscopic cells left behind.
  • Maintenance therapy: Ongoing, gentler treatment given after the main course has shrunk the cancer, to hold it in check for as long as possible rather than to shrink it further.

Tests and results to bring

Newly diagnosed: Surgery + platinum-taxane ± bevacizumab ± HIPEC; PARP maintenance by HRD status.

Newly diagnosed stage I-II: Complete surgical staging; adjuvant carboplatin-paclitaxel for high-grade or stage IC-II disease; observation for low-risk stage IA-IB grade 1-2.

Newly diagnosed stage III-IV: surgery and chemotherapy: Primary debulking if complete resection is feasible, else 3 cycles neoadjuvant carboplatin-paclitaxel then interval debulking (with HIPEC in stage III, OVHIPEC-1) and 3 more cycles; add bevacizumab for high-risk or residual disease.

Biomarker results to ask for: BRCA1/2 (germline and somatic), HRD (myChoice), FRα IHC, CDH6, CA-125, PD-L1, Germline and somatic BRCA1/2, HRD genomic instability score (myChoice CDx, FoundationOne), Folate receptor alpha IHC (≥75% of cells at 2+ for mirvetuximab), PD-L1 CPS ≥1 (pembrolizumab, KEYNOTE-B96), KRAS/BRAF/NRAS (low-grade serous), CA-125 and HE4 (monitoring, ROMA index), Platinum-free interval (defines sensitive vs resistant), MMR/MSI (endometrioid, clear-cell), HER2 (mucinous, some clear-cell).

Scans and tests linked to this cancer: Companion diagnostics, Germline (hereditary) testing, HRD & BRCA testing, HRD genomic scar scores (GIS, LOH, HRDetect), Liquid biopsy (ctDNA), Serum tumour markers: proper use and misuse.

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call